Methylated ATM Gene May Predict Breast Cancer Risk

Share this content:

(ChemotherapyAdvisor) – The level of methylation in the ataxia telangiectasia mutated (ATM) gene from white blood cells (WBCs) may be used as a biomarker of breast cancer risk, according to a multinational team of researchers. This conclusion is based on a study entitled “Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk,” which is published in the May issue of Cancer Research

In this study, the investigators aimed to evaluate WBC DNA methylation of ATM as a biomarker of cancer risk. Investigators obtained prediagnostic peripheral blood samples from three prospective studies to determine the status and level of DNA methylation in two ATM genes. “Samples were from a case–control study derived from a cohort of high-risk breast cancer families (KConFab) and nested case–control studies in two prospective cohorts: Breakthrough Generations Study (BGS) and European Prospective Investigation into Cancer and Nutrition (EPIC),” the authors wrote. Methylation level was determined by DNA sequencing from 640 cases of invasive breast cancer and 741 controls.

The investigators reported that one of the ATM genes was correlated with an increased risk of breast cancer, but this observation was limited to women in the highest quintile [OR, 1.89; 95% confidence interval (CI), 1.36–2.64; P=1.64 × 10−4]. “No significant differences were found in estimates across studies or in analyses stratified by family history or menopausal status …a more consistent association was observed in younger than in older women…,” the investigators wrote.

Based on these data, the investigators concluded that “WBC DNA methylation levels at ATM could be a marker of breast cancer risk…”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs